Production of riboflavin

US10633684B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10633684-B2
Application numberUS-200913127618-A
CountryUS
Kind codeB2
Filing dateNov 9, 2009
Priority dateNov 7, 2008
Publication dateApr 28, 2020
Grant dateApr 28, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides an improved biotechnological production of riboflavin (also referred herein as vitamin B2) through modification in the operon containing the riboflavin biosynthetic genes (rib operon), in particular modifications of/in the leader sequences (rib leader) upstream of the corresponding riboflavin biosynthetic genes (rib operon). Furthermore, the present invention relates to genetically engineered microorganisms carrying said modified sequences, processes to generate said modified sequences/microorganisms and the use thereof for production of riboflavin.

First claim

Opening claim text (preview).

The invention claimed is: 1. A mutated Bacillus subtilis rib leader sequence of the riboflavin biosynthesis operon operatively linked to at least one downstream rib gene, wherein said mutated Bacillus subtilis rib leader sequence does not comprise a Bacillus subtilis rib leader terminator sequence and does comprise at least one ribO mutation, wherein said Bacillus subtilis rib leader terminator sequence consists of a contiguous sequence of nucleotides 231-263 of SEQ ID NO: 42, and said at least one ribO mutation is selected from the group consisting of a mutation of one of the following positions of SEQ ID NO:42: T31, G39, G40, G41, C55, C85, C86, G88, C93, A116, G121 and C128. 2. A mutated Bacillus subtilis rib leader sequence of the riboflavin biosynthesis operon operatively linked to at least one downstream rib gene and a constitutive promoter, wherein said mutated Bacillus subtilis rib leader sequence operably linked to a constitutive promoter comprises the nucleotide sequence of SEQ ID NO:67, 68, 69, 70 or 71. 3. The mutated Bacillus subtilis rib leader sequence of claim 1 fused to a constitutive promoter. 4. A riboflavin-producing microorganism genetically engineered with a mutated Bacillus subtilis rib leader sequence of claim 1 . 5. A riboflavin-producing microorganism according to claim 4 capable of producing at least 5% more riboflavin from a given carbon source compared to production of riboflavin using a wild-type microorganism. 6. A riboflavin-producing microorganism according to claim 4 wherein the accumulation of intact, full-length riboflavin mRNA is improved compared to a wild-type microorganism. 7. A method for production of riboflavin comprising culturing a microorganism with a carbon source under conditions whereby riboflavin is produced by said microorganism, said microorganism comprising the mutated Bacillus subtilis rib leader sequence of claim 1 . 8. A process for the production of a microorganism according to claim 4 comprising the steps of: (a) providing a microorganism capable of riboflavin production comprising a rib operon including leader sequences; and (b) genetically engineering said microorganism with a polynucleotide. 9. A process for the production of riboflavin comprising the use of a microorganism according to claim 4 and optionally isolating and/or purifying the produced riboflavin from the reaction mixture. 10. A process according to claim 9 wherein the microorganism is incubated in an aqueous medium under conditions that allow the production of riboflavin from a given substrate. 11. A process for the production of full-length mRNA transcripts from riboflavin biosynthetic genes in a riboflavin-producing microorganism comprising introducing into said microorganism a polynucleotide according to claim 1 . 12. The modified polynucleotide sequence according to claim 3 wherein the constitutive promoter is selected from P veg or P Spo15. 13. A mutated Bacillus subtilis rib leader sequence of the riboflavin biosynthesis operon operatively linked to at least one downstream rib gene, wherein said mutated Bacillus subtilis rib leader sequence does not comprise a Bacillus subtilis rib leader terminator sequence and does comprise at least one ribO mutation, wherein said Bacillus subtilis rib leader terminator sequence consists of a contiguous sequence of nucleotides 231-263 of SEQ ID NO:42, and said at least one ribO mutation is selected from the group consisting of a mutation of one of the following positions of SEQ ID NO:42: T31, G39, G40, G41, C55, C85, C86, G88, C93, A116, G121 and C128, and wherein said mutated rib leader sequence leads to relaxation or reduction of a repressive effect of a non-modified Bacillus subtilis rib leader sequence on expression of a downstream rib gene when said mutated rib leader sequence is expressed in a riboflavin biosynthesis operon as compared to expression of said non-modified Bacillus subtilis rib leader sequence in the riboflavin biosynthesis operon. 14. A mutated Bacillus subtilis rib leader sequence of the riboflavin biosynthesis operon operatively linked to at least one downstream rib gene, wherein said mutated Bacillus subtilis rib leader sequence does not comprise a Bacillus subtilis rib leader terminator sequence and does comprise at least one ribO mutation, wherein said Bacillus subtilis rib leader terminator sequence consists of a contiguous sequence of nucleotides 231-263 of SEQ ID NO:42, and said at least one ribO mutation is selected from the group consisting of a mutation of one of the following positions of SEQ ID NO:42: G39, G40, G41, C85 and G121.

Assignees

Inventors

Classifications

  • from Bacillus (G) · CPC title

  • C12P25/00Primary

    Preparation of compounds containing alloxazine or isoalloxazine nucleus, e.g. riboflavin · CPC title

  • Genes encoding for enzymes or proenzymes · CPC title

  • C12N15/75Primary

    for Bacillus · CPC title

  • DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10633684B2 cover?
The present invention provides an improved biotechnological production of riboflavin (also referred herein as vitamin B2) through modification in the operon containing the riboflavin biosynthetic genes (rib operon), in particular modifications of/in the leader sequences (rib leader) upstream of the corresponding riboflavin biosynthetic genes (rib operon). Furthermore, the present invention rela…
Who is the assignee on this patent?
Lehmann Martin, Hohmann Hans Peter, Laudert Dietmar, and 2 more
What technology area does this patent fall under?
Primary CPC classification C12P25/00. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).